Internal Medicine, Hematology & Oncology · Boston, MA
NPI
1790746907
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
450 Brookline Ave, Dana Farber Cancer Institute
Boston, MA, 02215
Phone (617) 632-3468
Groups this clinician bills Medicare through
Medicare paid, 2024
$94K
810 services
Medicare patients, 2024
291
Average age 74
Drug cost, 2024
$2.0M
556 prescriptions
Company payments, 2025
$60.22
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by J Paul Marcoux II was code 99215 (office e&m - established), 606 times for 208 patients. In total J Paul Marcoux II billed 810 services in 12 codes, and Medicare paid $94K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-12-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 606 | 208 | $120.34 | $73K |
| 99205 Office E&M - New | Office | 73 | 73 | $147.51 | $11K |
| 99214 Office E&M - Established | Office | 32 | 27 | $101.41 | $3,245 |
| 99232 Hospital E&M - Subsequent | Facility | 28 | 16 | $65.52 | $1,835 |
| 99443 Telephone Services | Office | 23 | 20 | $74.12 | $1,705 |
| 99442 Telephone Services | Office | 17 | 14 | $54.86 | $933 |
By year: 2022 $79K for 661 services; 2023 $80K for 686 services; 2024 $94K for 810 services.
Medicare prescription drug claims, 2024
In 2024, the drug J Paul Marcoux II prescribed most often to Medicare patients was Gabapentin, with 55 prescriptions and refills. In total J Paul Marcoux II wrote 556 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 55 | 63 | 15 | $636 |
| Tagrisso Osimertinib Mesylate | 45 | 45 | Under 11 | $740K |
| Dexamethasone Generic | 44 | 47 | 25 | $756 |
| Ondansetron Odt Ondansetron | 27 | 27 | 20 | $231 |
| Lorbrena Lorlatinib | 26 | 26 | Under 11 | $481K |
| Prednisone Generic | 25 | 33 | 17 | $129 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 19 | 19 | 11 | $75.43 |
| Lumakras Sotorasib | 18 | 18 | Under 11 | $340K |
| Prochlorperazine Maleate Generic | 16 | 16 | 11 | $164 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 15 | 15 | 12 | $78.53 |
| Lorazepam Generic | 14 | 14 | 12 | $53.72 |
| Tepmetko Tepotinib Hcl | 14 | 14 | Under 11 | $317K |
| Olanzapine Generic | 14 | 15 | Under 11 | $133 |
| Oxycodone Hcl Generic | 13 | 13 | 13 | $198 |
| Omeprazole Generic | 12 | 24 | Under 11 | $140 |
Brand drugs: 136 claims; generic drugs: 420 claims; opioid claims: 35.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid J Paul Marcoux II $60.22 ($60.22 in general payments such as food, travel and fees) from 2 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $43.25.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.